Measurement of blood E2F3 mRNA in prostate cancer by quantitative RT-PCR: a preliminary study

References

• Adams MR, Sears R, Nuckolls F, Leone G, Nevins J. Complex transcription regulatory mechanisms control expression of the E2F3 locus. Molecular and Cellular Biology 2000; 20: 3633–3639
   PubMedGoogle Scholar
• Andersen CL, Jensen JL, Ørntoft TF. Normalisation of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalisation, applied to bladder and colon cancer data sets. Cancer Research 2004; 64: 5245–5250
   PubMed Web of Science ®Google Scholar
• Bostwick DG, Foster CS. Predictive factors in prostate cancer: current concepts from the 1999 College of American Pathologists Conference on solid tumour prognostic factors and the 1999 World Health Organization second international consultation on prostate cancer. Seminars in Urologic Oncology 1999; 17: 222–272
   PubMedGoogle Scholar
• Brawer MK. Prostate-specific antigen. Seminars in Surgical Oncology 2000; 18: 3–9
   Google Scholar
• Bustin SA. Absolute quantification of mRNA using real-time reverse-transcription polymerase chain reaction assays. Journal of Molecular Endocrinology 2000; 25: 169–193
   PubMed Web of Science ®Google Scholar
• Bustin SA, Nolan T. Pitfalls of quantitative real-time reverse-transcription polymerase chain reaction. Journal of Biomolecular Techniques 2004; 15: 155–166
   PubMedGoogle Scholar
• Dearnaley DP, Kirby RS, Kirk D, Malone P, Simpson RJ, Williams G. Diagnosis and management of early prostate cancer. Report of a British Association of Urological Surgeons Working Party. British Journal of Urology 1999; 83: 18–33
   Google Scholar
• DeGregori J. The genetics of the E2F family of transcription factors: shared functions and unique roles. Biochimica et Biophysica Acta 2002; 1602: 131–150
   PubMed Web of Science ®Google Scholar
• DeMarzo AM, Nelson WG, Isaacs WB, Epstein JI. Pathological and molecular aspects of prostate cancer. Lancet 2003; 361: 955–964
   PubMed Web of Science ®Google Scholar
• Eder IE, Bektic J, Haag P, Bartsch G, Klocker H. Genes differentially expressed in prostate cancer. British Journal of Urology 2004; 93: 1151–1155
   Google Scholar
• Feber A, Clark J, Goodwin G, Dodson AR, Smith PH, Fletcher A, Edwards S, Flohr P, Falconer A, Roe T, Kovacs G, Dennis N, Fisher C, Wooster R, Huddart R, Foster CS, Cooper CS. Amplification and overexpression of E2F3 in human bladder cancer. Oncogene 2004; 23: 1627–1630
   PubMed Web of Science ®Google Scholar
• Foster CS, Falconer A, Dodson AR, Norman AR, Dennis N, Fletcher A, Southgate C, Dowe A, Dearnaley D, Jhavar S, Eeles R, Feber A, Cooper CS. Transcription factor E2F3 overexpressed in prostate cancer independently predicts clinical outcome. Oncogene 2004; 23: 5871–5879
   PubMed Web of Science ®Google Scholar
• Ghossein RA, Bhattacharya S, Coit DG. Reverse transcriptase polymerase chain reaction (RT-PCR) detection of melanoma-related transcripts in the peripheral blood and bone marrow of patients with malignant melanoma. What have we learned? Recent Results. Cancer Research 2001; 158: 63–77
   Google Scholar
• Ginzinger DG. Gene quantification using real-time quantitative PCR: An emerging technology hits the mainstream. Experimental Haematology 2002; 30: 503–512
   PubMed Web of Science ®Google Scholar
• Grönberg H. Prostate cancer epidemiology. Lancet 2003; 361: 859–864
   PubMed Web of Science ®Google Scholar
• Hampton R, Walker M, Marshall J, Juhl H. Differential expression of carcinoembryonic antigen (CEA) splice variants in whole blood of colon cancer patients and healthy volunteers: implication for the detection of circulating colon cancer cells. Oncogene 2002; 21: 7817–7823
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57–70
   PubMed Web of Science ®Google Scholar
• Hunter T, Pines J. Cyclins and cancer II: cyclin D and CDK inhibitors come of age. Cell 1994; 79: 573–582
   PubMed Web of Science ®Google Scholar
• Krumholtz JS, Carvalhal GF, Ramos CG, Smith DS, Thorson P, Yan Y, Humphrey PA, Roehl KA, Catalona WJ. Prostate-specific antigen cut-off of 2.6 ng/ml for prostate cancer screening is associated with favourable pathologic tumour features. Urology 2002; 60: 469–473
   Google Scholar
• Kumar-Sinha C, Chinnaiyan AM. Molecular markers to identify patients at risk for recurrence after primary treatment for prostate cancer. Urology 2003; 62(Supplement 6B)19–35
   Google Scholar
• Latchman D. 1998. Gene Regulation: a eukaryotic perspective. UK: Stanley Thornes Ltd, 304–305.
   Google Scholar
• McIntyre IG, Spreckley K, Clarke RB, Anderson E, Clarke NW, George NJ. Optimization of the reverse transcriptase polymerase chain reaction for the detection of circulating prostate cells. British Journal of Cancer 2000; 83: 992–997
   Google Scholar
• Morrison TB, Weis JJ, Wittwer CT. Quantification of low-copy transcripts by continuous SYBR Green I monitoring during amplification. Biotechniques 1998; 24: 954–962
   PubMed Web of Science ®Google Scholar
• Muller H, Bracken AP, Vernell R, Moroni MC, Christians F, Grassilli E, Prosperini E, Vigo E, Oliner JD, Helin K. E2Fs regulate the expression of genes involved in differentiation, development, proliferation and apoptosis. Genes and Development 2001; 15: 267–285
   PubMed Web of Science ®Google Scholar
• Nelson WG, De Marzo AM, Isaacs WB. Mechanisms of disease: prostate cancer. New England Journal of Medicine 2003; 349: 366–381
   PubMed Web of Science ®Google Scholar
• Nevin JR. Towards an understanding of the functional complexity of the E2F and retinoblastoma families. Cell Growth and Differentiation 1998; 9: 585–593
   Google Scholar
• Oeggerli M, Tomovska S, Schraml P, Calvano-Forte D, Schafroth S, Simon R, Gasser T, Mihatsch MJ, Sauter G. E2F3 amplification and overexpression is associated with invasive tumour growth and rapid tumour cell proliferation in urinary bladder cancer. Oncogene 2004; 23: 5616–5623
   PubMed Web of Science ®Google Scholar
• O'Hara SM, Moreno JG, Zweitzig DR, Gross S, Gomella LG, Terstappen LW. Multigene reverse transcription-PCR profiling of circulating tumour cells in hormone-refractory prostate cancer. Clinical Chemistry 2004; 50: 826–835
   PubMed Web of Science ®Google Scholar
• Ohl F, Junf M, Xu C, Stephan C, Rabien A, Burkhardt M, Nitsche A, Kristiansen G, Loening SA, Radonic A, Jung K. Gene expression studies in prostate cancer tissue: which reference gene should be selected for normalization?. Journal of Molecular Medicine 2005; 83: 1014–1024
   PubMed Web of Science ®Google Scholar
• Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000: the global picture. European Journal of Cancer 2001; 37: S4–66
   PubMed Web of Science ®Google Scholar
• Pfaffl MW. 2004. Quantification strategies in real-time PCR. In: Bustin SAA–Z of quantitative PCR. La JollaCA, USA: International University Line, Chapter 3.
   Google Scholar
• Rasmussen R. Quantification on the LightCycler. Rapid Cycle Real-time PCR, Methods and Applications, S Meuer, C Wittwer, K Nakagawara. Springer Press, Heidelberg 2001; 21–34
   Google Scholar
• Roche Applied Science Technical Note No. LC 13/2001: Relative Quantification.
   Google Scholar
• Sakr WA, Haas GP, Cassin BF, Pontes JE, Crissman JD. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. Journal of Urology 1993; 150: 379–385
   PubMed Web of Science ®Google Scholar
• Schott A, Vogel I, Krueger U, Kalthoff H, Schreiber HW, Schmiegel W, Henne-Bruns D, Kremer B, Juhl H. Isolated tumour cells are frequently detectable in the peritoneal cavity of gastric and colorectal cancer patients and serve as a new prognostic marker. Annals of Surgery 1998; 227: 372–379
   PubMed Web of Science ®Google Scholar
• Szabo A, Perou CM, Karaca M, Perreard L, Quackenbush JF, Bernard PS. Statistical modelling for selecting housekeeper genes. Genome Biology 2004; 5: R59.1–R59.10
   Google Scholar
• Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RG, Otte AP, Rubin MA, Chinnaiyan AM. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002; 419: 624–629
   PubMed Web of Science ®Google Scholar
• Warrington JA, Nair A, Mahadevappa M, Tsyganskaya M. Comparison of human adult and fetal expression and identification of 535 housekeeping/maintenance genes. Physiological Genomics 2000; 2: 143–147
   PubMed Web of Science ®Google Scholar
• Welsh JB, Sapinoso LM, Su AI, Kern SG, Wang-Rodriguez J, Moskaluk CA, Frierson HF, Jr, Hampton GM. Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Research 2001; 61: 5974–5978
   PubMed Web of Science ®Google Scholar